The 6 entries below are adverse events, or their absence, as 5 cited studies recorded them (4 in humans). Each row names the population the effect was seen in and links to the source.
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
Regulatory status in the United States
Status reviewed September 16, 2026
FDA-approved drug
No. Cagrilintide is not an FDA-approved drug for any use.
503A compounding
Not on FDA's 503A lists. Not nominated for, or not currently on, FDA's list of bulk drug substances permitted for 503A compounding.
How it is obtained
Sold only as a research chemical labeled “not for human use.” No lawful prescription pathway exists for it today.
Cagrilintide is not an FDA-approved drug for any use. It is not on FDA's 503A bulk drug substances lists, and no lawful prescription pathway for a compounded version was identified at the review date. Products sold as "research use only" are not intended for human use and are not a lawful substitute for a prescription. This status comes from the site's regulatory review, not from the studies cited on this page.
What the studies recorded
Adverse events, or their absence, as the cited studies recorded them in the populations they enrolled.
Reported effect
Context in the study
Source
Gastrointestinal disorders including nausea, constipation and diarrhoea, plus administration-site reactions
Most frequent adverse events in the phase 2 dose-finding trial of once-weekly cagrilintide alone; more participants on cagrilintide had gastrointestinal adverse events than on placebo (41%-63% vs 32%), primarily nausea (20%-47% vs 18%)
Treatment discontinuation, mostly due to adverse events
Permanent treatment discontinuation occurred in 73 of 706 participants (10%) similarly across treatment groups in the phase 2 trial, mostly due to adverse events (n=30, 4%)
Reported by 79.6% in the cagrilintide-semaglutide group versus 39.9% in the placebo group in REDEFINE 1; mainly transient and mild-to-moderate in severity
Reported by 72.5% of patients on cagrilintide-semaglutide versus 34.4% on placebo in adults with type 2 diabetes (REDEFINE 2); most were transient and mild or moderate in severity
A row that says no adverse events were reported means the study did not record any in the people or animals it followed, for as long as it followed them. Small pilots with days of follow-up cannot detect uncommon or delayed effects, and animal findings do not transfer to people. A study that did not look for an effect will not have reported one.
Effects listed here come only from the cited studies. Reports from clinics, vendors, or forums are not included because they cannot be checked against a stated population and method. The Cagrilintide profile covers the same studies in context.
Frequently asked questions
What side effects were reported?
Gastrointestinal events dominate. In the phase 2 trial of cagrilintide alone, the most frequent adverse events were gastrointestinal disorders such as nausea, constipation and diarrhoea, plus administration-site reactions, with gastrointestinal events in 41%-63% of cagrilintide groups versus 32% on placebo (Lancet dose-finding trial, 2021). With the combination, gastrointestinal adverse events affected 79.6% versus 39.9% on placebo in REDEFINE 1 (REDEFINE 1, 2025) and 72.5% versus 34.4% in REDEFINE 2, mostly transient and mild or moderate (REDEFINE 2, 2025). A pooled analysis reported no increase in serious adverse events (CagriSema meta-analysis, 2026).
What is still unknown about cagrilintide?
Long-term outcome data are the main gap. Reviewers note that data on mortality and cardio-renal-metabolic events, and long-term follow-up on safety and weight maintenance, are still needed for emerging obesity pharmacotherapies including CagriSema (Emerging pharmacotherapies systematic review, 2024). Information in adolescents remains limited compared with adults (Adolescent obesity review, 2026). Effects on bone during weight loss are being studied in a recruiting trial comparing cagrilintide, semaglutide, CagriSema and placebo in postmenopausal women with obesity (NCT07010432), and tolerability of switching from semaglutide to CagriSema is the subject of a registered but not-yet-recruiting study (NCT07817251).
Where Cagrilintide is prescribed
A licensed prescriber can weigh these reports against your history. These programs list Cagrilintide on their own sites; availability depends on the regulatory status above and on your state.
Disclosure: links marked sponsored below are affiliate links. If you sign up or buy through one we may earn a commission, at no extra cost to you. Commissions do not change what we list, how we rank it, or what the research pages say. How we make money.
Hone Health
Compounds
sermorelin, nad
Pricing
From $175/month. Published on honehealth.com at check time: sermorelin $175/month; other medications listed at $20 to $199/month plus membership. Membership is $25/month (Basic: labs every 6 months, consults purchased separately) or $155/month (Premium: labs, physician consults and medication access); the initial 50+ biomarker test is $65. State coverage is not stated on the pages we read, so it is recorded here as nationwide until confirmed.
From $99/month. Published on livevital.io at check time: $99 to $299 per month depending on the peptide, sold as 10-week courses. GHK-Cu $99/month; BPC-157 and Wolverine $116/month; Glow, Klow and MOTS-c $149/month; tesamorelin $166/month. The 15-minute phone consult is free and HSA/FSA funds are accepted.io.
From $164/month. Published on joinmidi.com at check time: Midi compounded GLP-1 and GLP-1/GIP from $164 per 4-week supply including shipping and supplies; visits are billed to insurance where in-network or $150 to $250 self-pay; brand-name GLP-1s are sent to a pharmacy of choice at the insurance price. A lower-strength weekly plan is advertised from $34 per week for eligible patients. The GLP-1 page notes that compounded products are not available in every state.